Ruifuda

Based in China, Ruifuda is an assisted reproduction company specializing in advanced medical technologies aimed at enhancing fertility treatments and improving reproductive health outcomes. Founded in 2018 in Lianyungang, China, Ruifuda focuses on assisted reproduction technologies. The firm has engaged in 2 significant funding rounds, with the most recent round completed on June 11, 2025. The company operates independently with no reported subsidiaries.

Ruifuda provides a comprehensive suite of assisted reproductive technologies designed to address various challenges in fertility treatments. Their core offerings include innovative medical solutions that enhance operational efficiency for healthcare providers. The company serves clients across Asia, Europe, and North America, catering to both small and large healthcare organizations seeking tailored reproductive health solutions. Ruifuda generates revenue through a diverse transaction structure that includes direct sales of its reproductive health technologies and partnerships with healthcare facilities.

Clients typically engage with the firm through subscription models for ongoing support, complemented by bulk purchases of flagship technologies. The revenue model supports both recurring income and one-time sales, ensuring financial stability. In June 2025, Ruifuda raised an undisclosed amount in Series B funding led by China International Capital Corporation, alongside participation from Park Yu (Jiangsu) Private Equity Fund Management Co. , Ltd.

The company plans to utilize these funds for technology research and development of core products, expand into domestic and overseas markets, upgrade capacity, and enhance team building initiatives. Specific strategies for market development include targeting new geographic regions to increase their presence in the assisted reproduction industry.